Lenalidomid Stada (Lenalidomide)

Lenalidomid Stada is used in several hematologic malignancies that involve abnormal plasma‑cell or lymphoid proliferation.

• Multiple myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease.
• Myelodysplastic syndromes with del(5q): induces transfusion independence and cytogenetic remission in eligible patients.
• Mantle‑cell lymphoma: contributes to disease control when combined with standard chemo‑immunotherapy.
• Follicular lymphoma: used as part of combination regimens to achieve durable remissions.

• Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, altering substrate specificity and promoting ubiquitination of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). Their degradation reduces survival signaling in malignant cells, inhibits angiogenesis, and modulates immune effector functions, collectively producing anti‑tumor activity.

Lenalidomid Stada may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Neutropenia: reduced neutrophil count.
• Anemia: lowered red blood cell levels.
• Thrombocytopenia: decreased platelet count.
• Fatigue: persistent tiredness.
• Nausea: upset stomach and vomiting.
• Diarrhea: loose stools.

Serious or Rare Side Effects

• Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
• Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Secondary primary malignancies: emergence of new cancers.
• Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.
• Severe infections: opportunistic or life‑threatening bacterial, viral or fungal infections.

Prior to initiating Lenalidomid Stada, clinicians should consider several safety measures and monitoring requirements.

• Pregnancy: contraindicated (Category X); ensure effective contraception for women of childbearing potential.
• Thromboembolic risk: assess baseline risk and consider prophylactic anticoagulation when indicated.
• Renal impairment: evaluate kidney function and adjust monitoring frequency as needed.
• Hematologic monitoring: perform regular complete blood counts to detect cytopenias early.
• Drug interactions: review concomitant medications, especially CYP3A4 inhibitors or inducers.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomid Stada can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase lenalidomide exposure.
• Live vaccines: heightened risk of severe infection due to immunosuppression.
• Anticoagulants (e.g., warfarin): increased bleeding risk when combined with lenalidomide‑induced thrombocytopenia.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug levels and diminish therapeutic effect.
• Antiplatelet agents (e.g., aspirin, clopidogrel): additive risk of bleeding.
• Other immunomodulatory agents (e.g., pomalidomide, thalidomide): may enhance myelosuppression.